Generic Name: obinutuzumab

Pronunciation: N/A

Abbreviation: N/A

Other Market Name: N/A

Drug Class: Targeted Therapy Medications

Company: Genentech

Approval Status: Approved

Generic Version Available: No

Experimental Code: N/A

Drug Indication

Gazyva is a monoclonal antibody approved for follicular lymphoma and chronic lymphocytic leukemia, and used for the similar blood cancer small lymphocytic lymphoma, in combination with chemotherapy.

General Info

Gazyva is an antibody that binds to the CD20 receptor on B cells that grow out of control in people with leukemia and lymphoma. This helps immune cells recognize and attack the cancer.


Dosing Info:

Gazyva is administered as an intravenous infusion. It is given on three or four days during the first month, then once monthly or every two months.

Side Effects

Common side effects include infusion reactions, fever, diarrhea, constipation, cough and upper respiratory tract infections. It can cause depletion of white blood cells (neutropenia) and platelets (thrombocytopenia), which can lead to infections and easy bleeding. Tumor lysis syndrome, or metabolic abnormalities that can occur when many cancer cells are killed at once, is a less common but potentially serious side effect.

For More Info:

Co-Pay Program Info:

Patient Assistance Program Info:

Last Reviewed: September 21, 2018